The BAG1 Knockout SK-HEP-1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population derived from the SK-HEP-1 hepatic adenocarcinoma cell line, featuring targeted disruption of the BAG1 gene. This loss-of-function model has been generated using a pool of edited cells to introduce permanent gene inactivation while preserving the experimental versatility of a mixed genetic background. The polyclonal format ensures broad representation of knockout variants without clonal selection, making it suitable for functional studies where population-level effects are paramount.
The parental SK-HEP-1 cell line is an extensively characterized adherent epithelial model originally isolated from the ascitic fluid of a male patient diagnosed with liver adenocarcinoma. These cells are widely employed as a robust in vitro system for investigating hepatocellular carcinoma biology, angiogenesis, and tumorigenesis. The SK-HEP-1 background supports mechanistic interrogation of oncogenic signaling networks, drug response profiling, and metastasis-associated processes, providing a physiologically relevant context for BAG1 gene ablation.
BAG1 encodes a multifunctional co-chaperone that modulates protein homeostasis and anti-apoptotic signaling. Mechanistically, BAG1 interacts directly with Hsp70/Hsc70 and the anti-apoptotic proteins BCL-2 and BCL-XL, enhancing their stability and chaperone-mediated functions. It is activated by extracellular stimuli such as EGF, PDGF, and TNF-??, and functions downstream of MAPK/ERK and PI3K/AKT cascades. Transcriptionally, BAG1 is regulated by TP53 and NF-??B, and it associates with nuclear hormone receptors to co-regulate target gene expression. Additionally, BAG1 interacts with Raf-1 and ubiquitin ligases, integrating survival signals from the heat shock response and oxidative stress pathways.
In the liver cancer context of SK-HEP-1 cells, disruption of BAG1 is predicted to attenuate anti-apoptotic defenses, impair stress adaptation, and dysregulate key proliferative pathways, including the Raf/MEK/ERK and AKT/mTOR axes. Consequently, this knockout model offers a powerful tool to dissect the molecular underpinnings of apoptosis resistance, chaperone-mediated cytoprotection, and signal transduction in hepatic adenocarcinoma. The polyclonal nature of the knockout population recapitulates tumor heterogeneity, enabling more physiologically meaningful assessments of BAG1-dependent phenotypes compared to monoclonal derivatives.
Researchers can utilize these BAG1 knockout cells in diverse experimental workflows. Representative assays include western blotting and RT-qPCR for BAG1 and BCL-2 expression validation, Annexin V apoptosis and MTT viability assays to quantify cell death, co-immunoprecipitation to probe Hsp70 interactions, and flow cytometry for apoptosis markers. Phospho-AKT and phospho-ERK analysis reveals pathway alterations, while migration and invasion assays test metastatic potential. Drug sensitivity studies with cisplatin explore chemoresistance mechanisms. For further information regarding this product, please contact Ascent Research.
